Pronto disponible para inscripción

This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

AbbVie M24-122 (Solid Tumors) - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to find out if an experimental drug called ABBV-303 (the study drug) is a safe and effective option for various solid tumor forms of cancer.

¿Cuál es la Condición que se está estudiando?

Solid Tumor Cancers (List in Eligibility Section)

¿Quién puede participar en el Estudio?

Adults ages 18+ who:

Are diagnosed with solid tumor cancer (including non-small cell lung cancer, gastroesophageal adenocarcinoma, head and neck squamous cell carcinoma, colorectal cancer, or renal cell cancer) that has spread
Have received standard therapy options for their type of cancer

For more information about who can join this study, please contact the study team at cci-trialreferrals@duke.edu or 919-681-6468.

Grupo etario

Adultos

¿Qué Implica?

Si elige unirse a este estudio, podrá:

Take the study drug alone or in combination with a drug called budigalimab
Have physical exams, blood draws, and give urine samples
Have imaging scans (CT and/or MRI)
Have heart tests (ECG)

Detalles del Estudio

Título Completo

A Phase 1 first-in-human, open-label study evaluating the safety, pharmacokinetics, and efficacy of ABBV-303, as monotherapy and in combination with budigalimab (ABBV-181), in adult subjects with advanced solid tumors

Investigador Principal